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Background: Interleukin-12 (IL-12) has long been considered to be effective in triggering an anticancer immune
response, however, the dosage has been limited by potential systemic immunotoxicity. Since focused ultrasound
(FUS) has been confirmed to temporally and locally open the blood–brain barrier (BBB), the purpose of this study
was to elucidate the possibility of combining FUS-induced BBB opening with IL-12 delivery to enhance the anticancer
immunological response for glioma treatment.
Methods: FUS energy combined with microbubble administration was delivered transcranially to open BBB, and C-6
glioma rats were used in this study. The efficacy in inducing BBB opening and the corresponding immunological
response were primarily evaluated in normal animals. The anticancer immune-triggering chemokine, IL-12, was
intraperitoneally administered during the treatment phase to evaluate the effect of immunological response on tumor
progression. Glioma animals were sub-grouped to evaluate the effect of the immune response in suppressing glioma
when IL-12 was combined with FUS-induced BBB opening. We performed flow cytometry to verify consequent
immune cell population changes of peripheral/tissue lymphocytes as well as macrophages from the animals. Brain
sections of sacrificed animals were also used for histological and immunohistochemical analysis. IL-12 level among
experimental groups were measured via ELISA analysis. We also analyzed survival and followed tumor progression
in vivo via T2-weighted magnetic resonance imaging.
Results: FUS-induced BBB opening had no obvious effect on the T lymphocytes population in normal animals, either
in the brain or systemically. Yet, it triggered mild changes in the tumor-infiltrating lymphocyte (TIL) population,
particularly in numbers of CD3+CD8+ cytotoxic T lymphocytes (CTLs) in the tumor region. IL-12 administration
triggered a profound increase in all TIL populations, including CD3+CD4+ T helper cells (Th), CTL, and CD4+CD25+
regulatory T cells (Treg), but combined FUS-BBB opening with IL-12 administration produced the most significant IL-12
increase, CTL increase and CTL/Treg ratio increase, thus contributing to the most significant suppression of tumor
progression and increased animal survival.
Conclusion: This study provides evidence that FUS-BBB opening can enhance immune-modulating agent delivery to
the brain, which improve the anticancer immune response in brain tumor treatment.
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Nearly 260,000 patients worldwide are diagnosed annu-
ally with primary malignant brain cancers, among which,
more than 50% are reported to have glioblastoma multi-
forme (GBM) [1]. GBM is the most common malignant
brain cancer in adults, and it is responsible for half of
cancer patients’ deaths. The median survival times are
reported to be 5–15 years for low-grade glioma patients,
but only 9–12 months for high-grade glioma patients
[2,3]. The current approach for brain tumor therapy is
surgical resection with radiotherapy, which is typically
accompanied by adjuvant and chemotherapy or other
therapeutic molecule substance delivery into the tumor
site [4,5]. Unfortunately, the therapeutic efficacy of most
drugs is significantly limited due to the structure of the
blood–brain barrier (BBB) or blood-tumor barrier, which
limits the penetration of the therapeutic agents and abil-
ity to reach therapeutic dose at the target tumor site.
The integrity of the BBB in the brain tumor is typically
highly heterogeneous, resulting in highly variable BBB
permeability within different tumor areas. The BBB is
usually most permeable in the tumor core, whereas it re-
mains relatively intact in the peripheral regions of the
tumor [6]. The BBB of the peripheral glioma has been
shown to remain highly functional [7-9], and previous
clinical studies have demonstrated that brain tumor cells
can migrate great distances from the enhancing regions
of the tumors [10]. As a result, current therapeutic sub-
stance delivery into brain tumors faces several difficult
challenges.
Passive brain-tumor immunotherapy is a brain-targeting
delivery strategy that faces the same challenges of limited
blood–brain permeability caused by the BBB. The concept
of passive brain-tumor immunotherapy typically refers to
the delivery of immune-effector cells and/or a variety of
molecules including monoclonal antibodies and cytokines
into brain tumors. The aim is to deliver cytokines or other
immune-triggering substances at a sufficiently high con-
centration locally so that they can effectively trigger an
antitumor immune response and establish long-term im-
munity against tumor recurrence in the host. There have
been attempts to deliver interleukin-2 (IL-2) [11,12],
interleukin-4 (IL-4) receptors [13,14], interleukin-12 (IL-
12) [15], interleukin-13 (IL-13) receptor protein [16],
transferring-diphtheria toxin [17], tumor growth factor-
gamma, and tumor-specific cytotoxic T lymphocytes
(CTLs) [18]. However, to overcome BBB blockage, most
of the immune-triggering substance are delivered through
local injection, making the procedure invasive. Among the
above-mentioned immune-triggering substances, IL-12 is
of particular interest due to its role in immunity and
tumor angiogenesis. First, IL-12 has been reported to pos-
sess anti-angiogenic properties and have an anti-glioma ef-
fect because it can stimulate an antitumor immuneresponse. Liu et al. reported the use of a replication-
deficient adenoviral vector encoding IL-12 for treatment
of a murine glioma model, and demonstrated that intratu-
moral delivery of gene-transfer IL-12 reduced tumor vol-
ume and prolonged survival in a GL-26 glioma model
[19]. Using a continuous infusion system, Jean et al. dem-
onstrated significant tumor regression using local intracra-
nial cytokine delivery [20]. On the other hand, Salmaggi
et al. analyzed the intracavitary level of vascular endothe-
lial growth factor (VEGF) and IL-12 in 45 patients, and
found that higher intracavitary concentration of VEGF
and lower IL-12 corresponds to higher grade of glioma
and shorter patient survival [21]. This demonstrates that
there is a correlation between IL-12 level and brain tumor
prognosis. Although systemic administration of recombin-
ant IL-12 in a variety of rodent tumor models has demon-
strated promise in significantly suppressing tumor growth
and enhancing animal survival [22,23], the success is pri-
marily limited because the BBB prevents the achievement
of therapeutic levels in patients, thereby increasing the
systemic concentration and the immune toxicity [24-26].
Focused ultrasound (FUS) exposure combined with
IV-injected microbubbles has recently been shown to lo-
cally and temporally open the blood–brain barrier, thus
providing a new opportunity for effective local drug de-
livery to brain tumors [27,28]. This BBB disruptive effect
was found to be temporary and reversible without dam-
aging surrounding central nervous system (CNS) tissues
or neural cells [29]. The intravenous administration of
microbubbles allows selective disruption of the BBB by
significantly reducing exposure to ultrasonic energy and
decreasing the influence on the parenchyma, thus min-
imizing the off-target effect [30]. Compared to other ap-
proaches such as local enhanced injections, or carotid
infusions, FUS thus presents a competitive and attractive
alternative for local induction of BBB disruption to in-
crease the local concentrations of chemotherapeutic
agents in GBM [31-33]. We therefore hypothesized that
there was an opportunity to locally enhance IL-12 deliv-
ery deposited at a targeted tumor site via FUS-induced
BBB opening to both improve brain tumor immunother-
apy and anti-angiogenesis for glioma therapy.
The aim of this study was to apply focused ultrasound
to temporally open the blood–brain barrier, and to evalu-
ate the synergistic effect from concurrent delivery of IL-12
to improve the glioma-suppressing effect. Figure 1 sum-
marizes the concept of synergetic FUS-induced BBB open-
ing to enhance targeted IL-12 delivery. In this study, we
aimed to verify that: (1) focused ultrasound can enhance
the local permeability to allow penetration of the thera-
peutic molecules into the brain tumor, (2) the systemic ad-
ministration of safety level IL-12 did not induce a
systemic cytotoxic immune effect, and (3) combined FUS-
induced BBB opening and safe IL-12 delivery can trigger
Figure 1 Schematic of FUS-induced BBB opening to enhance IL-12 delivery in brain glioma treatment.




All animal experiments were approved by the animal
committee (Chang-Gung University, Taoyuan, Taiwan)
and adhered to the experimental animal care guidelines.
Pathogen-free male Sprague–Dawley rats (200–225 g)
were purchased from the National Laboratory Animal
Center (Taipei, Taiwan). C6 glioma cells were harvested
by means of trypsinization and cultured at a concentra-
tion of 1 × 105 cells/mL for implantation. A total of 5 μL
of C-6 glioma cell suspension were injected at a depth of
4.5 mm from the brain surface. The injection was per-
formed over a 10-min period, and the needle was with-
drawn over another 2 min.
Control rats were injected with C6 glioma cells, but
received sham ultrasound procedure with no energy. A
second group of rats was subjected to focused ultra-
sound at the selected pressure level (5 W) at day 11, day
13, and day 15 after tumor implantation. A third group
of rats received a single dose per day for 5 days of IL-12
(0.3 μg/kg/day) via intraperitoneal injection (IP) from
day 11 to day 15 after they were injected with the tumor
cells. A fourth group of rats received 5-days IL-12
(0.3 μg/kg/day) IP combined with 3 times of 5-w focused
ultrasound on day 11, 13, and 15. There are 12 rats in
each group for flow cytometry, at least 12 rats in each
group for efficacy and magnetic resonance image (MRI)
study, and 3 rats in each group for immunohistochemi-
cal (IHC) study. Ten days after implantation, tumor sizeswere measured using 7 Tesla MRI scanner. Animals
were assessed longitudinally by MRI at one-week inter-
vals up to day 38 to determine tumor size. The animals
were anesthetized with 2% isoflurane throughout the
MRI imaging process, placed in an acrylic holder and
positioned in the center of the magnet. Tumor size was
quantified using T2-weighted images with the following
parameters: TR/TE = 2500 ms/68 ms, matrix size = 176 ×
256, FOV = 31 × 35 mm (resolution = 0.18 × 0.14 mm).
The treatment and evaluation timelines are shown in
Figure 2.
Focused ultrasound exposure
Animals were anesthetized with a mixture of oxygen
(with flow rate of 0.8 L/min) and 2% vaporized isoflur-
ane using an anesthesia vaporizer. The top of the cra-
nium was shaved with clippers, and a PE-10 catheter
was inserted into the tail vein for injections. The animal
was placed directly under an acrylic water tank with its
head attached tightly to the thin-film, 4 × 4 cm2 window
at the bottom of the tank. A focused ultrasound trans-
ducer (Sonic Concepts, Seattle, WA, USA; operating fre-
quency = 0.5 MHz, active element diameter = 64 mm,
radius curvature = 55 mm) driven by an arbitrary func-
tion generator (33220A, Agilent, Palo Alto, CA, USA)
with a radio-frequency power amplifier (150A100B,
Amplifier Research, Souderton, PA, USA) for RF signal
amplification and a power meter (Model-4421, Bird,
USA) for electrical power sensing was used. FUS expos-
ure was 5 or 20 Watt (W) in electric power, equivalent
to measured acoustic negative-peak pressures of 0.36 –
0.7 MPa. Before FUS exposure, a 0.1 mL/kg bolus of
Figure 2 FUS-BBB opening confirmation/ immune-response in normal rats and experimental timelines. (A) Gross brain sections to assess
Evans blue dye leakage in brain tissue exposed to 5-W FUS-induced BBB opening as well as the combined large-scaled erythrocyte extravasations
after 20-W FUS exposure). (B) Population comparison of CD3+CD4+, CD3+CD8+, CD4+CD25+ T lymphocytes in controlled, 5-W FUS-exposed,
and 20-W FUS-exposed normal animals. The CD3+CD4+, CD3+CD8+, and CD4+CD25+ cells specifically represent populations of helper T lymphocytes
(Th), cytotoxic T lymphocytes (CTL), and regulatory T lymphocytes (Treg), respectively. (n = 7 per group). (C) The experimental timeline.
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Milan, Italy) mixed with 0.2 mL of saline were injected
intravenously (IV), followed by flushing with 0.2 mL
heparin. A single sonication of burst mode ultrasound
was delivered to the animal (burst length = 100 ms, pulse
repetitive frequency = 1 Hz, exposure time = 90 s).
Detection of peripheral/tissue lymphocytes
The animals were sacrificed on the day16th after tumor
implantation. The organs (brain, mesenteric lymph nodes
(MLN) and spleen) were removed to determine the effect
of FUS combined with IL-12 treatment. The left brain was
chopped into small pieces using a razor blade and 1 g of
brain was incubated with 10 ml collagenase type IV
(1 mg/ml; GIBCO, CA, USA) in PBS buffer on a shaker
incubator at 100 rpm, 37°C for 30 min and washed with
RPMI1640 medium. Cells were passed through nylon
mesh, centrifuged at 1800 rpm for 3 minutes, and washed
with RPMI1640 media. Cell pellets were re-suspended in
8 ml RPMI1640 media and layered over 4 ml Ficoll(Pharmacia, Peapack, NJ) in a 15-ml centrifuge tube. After
centrifuging at 2000 rpm for 20 minutes with a deceler-
ation speed set at 2, the single-cell suspension was sepa-
rated from the Ficoll, and leukocytes were recovered from
the inter-phase.
Antibodies and flow cytometry
Anti-CD3-FITC, anti-CD4-APC, anti-CD8-PE, anti-CD11-
APC, anti-CD25-FITC and anti-CD45-FITC antibodies
were used for intracellular staining. TILs were washed
twice with Hank’s balanced salt solution (HBSS), then
fixed and permeabilized in Fix/Perm buffer according to
the manufacturer’s instructions for 30 min. Cells were
washed twice with permeabilization buffer and then incu-
bated with appropriate antibodies at 4°C for 30 min in the
dark. Unbound antibodies were removed by washing twice
with permeabilization buffer. Flow cytometry analyses
were performed on a three-color fluorescence FACS cali-
burcytometer using Cell Quest software (Becton-Dickinson,
CA, USA).
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To confirm the FUS-induced local immune response,
rats with tumors were sacrificed 2 hours after 5-W FUS
exposure on day 10. Paraformaldehyde-fixed and paraffin-
embedded tumors were used to prepare 10-μm thick
sections for IHC analysis. CD8+ marker (Santa Cruz; sc-
53063) was employed to specifically bind to CTLs (CD3+/
CD8+ TILs). For Treg cells (CD4+/CD25+ TILs), instead
of using CD25+ marker, FoxP3 marker (Biosussa; bs-
0269R) was employed because it specifically binds to Treg
cells. The adjacent sections were stained with hematoxylin-
eosin (HE) to observe histological changes after FUS
exposure.
IL-12 concentration measurement
To determine IL-12 concentration in brain tumor tissue,
four groups with control, FUS once, single dose of IL-12
IP and FUS+ IL-12 treatment were performed at day 11
after tumor implantation. There were eight tumor-
bearing rats for each group. Animals were sacrificed
24 hrs after treatment, with tumor tissues were collected
and homogenated to perform rat ELISA analysis (IL-
12p70 kits, Invitrogen).
Magnetic resonance imaging and analysis
Tumor-bearing rats were followed to monitor the pro-
gression of brain tumors. All MRI images were acquired
on a 7-Tesla magnetic resonance scanner (Bruker Clin-
Scan, Germany) and a 4-channel surface coil was used
on the top of the rat brain. The animals were anesthe-
tized through inhalation of 2% isoflurane throughout the
MRI process, placed in an acrylic holder and positioned
in the center of the magnet. In the tumor animal experi-
ment group, tumor size was quantified using turbo-spin-
echo based T2-weighted images with the following
parameters: pulse repetition time (TR)/echo time (TE) =
2000/41 ms; FOV = 33 × 50 mm2 (162 × 320 pixels); slice
thickness = 0.5 mm. The relative tumor size was esti-
mated by measuring the single image slide containing
the maximum tumor area, and animals were longitudin-
ally imaged every 7 days for up to 38 days after the 1st
MRI screening (i.e., day 10). Detailed experimental de-
signs were shown in Figure 2(C).
Statistical analysis and tumor volume measurement
Flow cytometry data are displayed as means ± standard
deviations. The Mann–Whitney U test was used for
the statistical analysis of differences between groups.
Log-rank test was used for survival analysis. Calcula-
tions were performed with PRISM (GraphPad, version
5.0). Differences were considered statistically significant
when p < 0.05 (labeled as *; further labeled as ** when
p < 0.001).Results
FUS has minimal effect on T cell components in normal
rat brain
Figure 2(A) shows typical brain sections stained with
Evans blue to mark the BBB-opened regions in normal
rats. FUS was applied to normal rats and was targeted to
the right striatum separately for 7 rats in each group. An
exposure power level of 5 W induced a successful BBB
opening effect, confirmed by Evans Blue staining in the
exposed brain hemisphere. HE stains also confirmed that
the brain tissues did not show any pathological changes
(not shown). When a higher exposure level of 20 W was
applied, the BBB-opened regions spread toward a wider
area, with RBCs extravasated in the exposure regions
(both confirmed by gross sections and HE stains).
The percentages of CD3+CD4+ lymphocytes, CD3+
CD8+ lymphocytes and CD4+CD25+ lymphocytes,
which represents helper T lymphocytes (Th), cytotoxic T
lymphocytes (CTL), and regulatory T lymphocytes (Treg),
respectively in normal rat brains for 3 groups (control,
5-W FUS exposure, and 20-W FUS exposure) are shown
in Figure 2(B). Aside from a slight increase in Th cells
(from 1.07 ± 0.47% to 2.14 ± 1.29% in 5 W exposure, but
without statistically significance (p = 0.12), there were no
changes in the populations of either CTL or Treg cells
after FUS exposure. Overall, the T lymphocyte popula-
tions were not significantly influenced by FUS exposure
either with an intact BBB opening or BBB-opening accom-
panied by RBC extravasations in normal animals. When
considering both successful BBB-opening and safety with
minimal possible tissue hazard induced by FUS exposure,
a FUS exposure level of 5 W was selected and applied in
subsequent animal experiments.
FUS exposure enhances IL-12 influence on regional CD8+
T cell component, while having almost no effect on the
systemic T cell component of brain tumor-bearing rats
Next, we designed an efficacy study to test whether FUS
and IL-12 have a synergistic effect on brain tumor treat-
ment and how this combined treatment influences both
systemic and tumor regional T lymphocyte components.
Tumor-bearing animals were sub-grouped as follows: (1)
control, (2) FUS-induced BBB opening alone, (3) IL-12
delivery alone, and (4) combined FUS-induced BBB
opening with IL-12 delivery.
Figure 3 shows the typical results from flow cytometric
analysis of the individual experimental groups with the
sample obtained from the brain tumor tissues. The cor-
responding quantitated lymphocyte populations are
shown in Figure 4. In the brain tumor region, the CD3+
CD4+ TIL population showed no significant increase in-
duced by FUS exposure alone when compared to sham
group (p = 0.016), but was significantly increased by ei-
ther IL-12 alone and combined FUS + IL-12 (22.16 ±
Figure 3 Representative flowcytometric analysis. Cell population comparison of CD3+CD4+, CD3+CD8+, CD4+CD25+ T lymphocytes and
CD45+CD11b+ macrophages of tumor tissues obtained from glioma-bearing animals in control, FUS alone, IL-12 alone, and combined IL-12+
FUS groups.
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spectively) (Figure 4(A)). CD3 + CD8+ lymphocytes were
both increased significantly (both p = 0.004) either by
FUS exposure alone (about 2 fold, from 1.99 ± 0.73% to
4.41 ± 0.58%) or by IL-12 administration alone (about 3
fold, from 1.99 ± 0.73% to 6.51 ± 2.01%), but with a most
profound and increase in FUS + IL-12 group (about 5
fold, from 1.99 ± 0.73% to 10.97 ± 5.96%) (Figure 4(B)).
The CD4+CD25+ lymphocyte population only signifi-
cantly responded to the FUS + IL-12 group (about 2 fold,
from 2.1 ± 0.74% to 4.11 ± 2.04%) (Figure 4(C)). There
was no influence on the CD45 + CD11b macrophage
population in the brain from the different treatments,
indicating that neither FUS exposure, IL-12 administra-
tion, nor combined did not triggered macrophage-enhanced differentiation and invasion in the tumor re-
gion (Figure 4(D)).
Compared to the change in the population of en-
hanced specific lymphocytes (particularly for CTLs or
Treg) induced either by FUS, IL-12, or the combination
FUS/IL-12, there were no significant changes in the
lymphocyte population percentages systemically, either
in spleen (Figures 4(E) and 5(H)) or in MLN (Figures 4
(I) and 5(L)). This indicates that combining FUS with
IL-12 administration only triggers the anticancer-specific
immunological response in the targeted tumor regions.
Regulatory T lymphocyte has been reported to play an
immune inhibitory role, and CD8 + T cells may act as ef-
fectors in the tumor microenvironment. We therefore
examined the changes in the ratios of CD8 + T cells/Treg
Figure 4 T lymphocyte and macrophage populations. CD3+/CD4+, CD3+/CD8+, CD4+/CD25+ T lymphocytes and CD45+/CD11b+
macrophages in glioma-bearing animals among the experimental groups (control, FUS-alone, IL-12 alone, and combined FUS/IL-12 groups).
(A-D) In brain tumor; (E-H) In spleen; (I-L) In mesenteric lymph nodes (MLN) (n = 12 per group).
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lustrated in Figure 5. There is no obvious CTL/Treg ra-
tio change in MLN and spleen (Figure 5(A) and (B)). On
the other hand, in glioma tissues, it was observed that
both FUS-BBB opening and IL-12 indeed resulted in an
increase in the CTL/Treg ratio when compared with the
control group (Figure 5(C); control group: 1.19 ± 0.38,
FUS group: 2.12 ± 0.70, p = 0.035; IL-12 alone group:
2.34 ± 0.91, p = 0.023). Combining FUS-BBB opening
with IL-12 administration provided the most profound
CTL/Treg ratio increase (increase to 3.0 ± 0.99, p <
0.001), indicating a synergistic effect on immunological
changes in the tumor region that are beneficial in the
suppression of glioma progression. This change in the
TIL population ratio was confirmed by IHC staining
(Figure 5(D) – (K); instead of using CD25+, Treg cells
were stained by FoxP3 marker to more specifically bind
to Treg cells), showing that FUS primarily induces an in-
crease in CTL population in tumors, but IL-12 can both
trigger CTL and Treg cell population increase in tumors.
Combined FUS exposure with IL-12 delivery therefore
produced a beneficial increase in the CTL to Treg popu-
lation ratio.FUS combined with IL-12 treatment increases IL-12 brain
deposition, inhibits brain tumor growth and improves
survival rate of rodents
Figure 6 shows the measured IL-12 concentration
desisted at brain tumor site among each experimental
groups. FUS exposure alone did not trigger IL-12 in-
crease in tumor and the IL-12 level was close to the
amount measured in control group (225.8 ± 98.4 versus
220.0 ± 61.8 pg/mg protein). IL-12 administrations alone
significantly increased local IL-12 deposition in tumor
about 1.89 fold (417.3 ± 168.5 pg/mg protein, p = 0.006).
While combing FUS-induced BBB opening with IL-12
administration, The local IL-12 concentration at brain
tumors can be further increased 2.87-fold when compared
to control (632.1 ± 358.2 pg/mg protein; p = 0.0034).
To assess glioma treatment efficacy, we used MRI to
longitudinally assess glioma progression from each ex-
perimental group. Figure 7 demonstrates typical T2 im-
ages used to quantitate tumor volume. The tumor
progression ratio during the first week (days 10–17) and
second week (days 17–24) were analyzed and presented
in Figure 8(A). Glioma-bearing animals without any
treatment showed fast tumor progression (from 11.41 ±
Figure 5 T lymphocyte population ratio and IHC histological confirmation. (A-C) T lymphocyte population ratio between CD3+/CD8+ (CTL)
and CD4+/CD25+ (Treg) among different experimental groups in spleen (A), in MLN (B), and in brain tumor (C). (n = 12 per group) (D-K)
Immunohistological chemistry (IHC) staining to show specific T lymphocyte distribution among the experimental groups ((D-G): Cytotoxic T
lymphocytes; Regulatory T lymphocytes; n = 3 per group).
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FUS-induced BBB opening alone did not suppress tumor
progression (from 11.41 ± 8.52 to 3.87 ± 4.81, p = 0.114
in week 1 and from 48.82 ± 30.17 to 35.95 ± 37.84, p = 0.345
in week 2 compared to control), whereas administrationFigure 6 Qantitated IL-12 concentrations deposited in brain
tumors among experimental groups (n = 8 per group).of IL-12 alone provided a moderate, but not statistically
significant, suppression of tumor growth (from 11.41 ±
8.52 to 3.62 ± 1.22, p = 0.038 in week 1 and from 48.82 ±
30.17 to 23.62 ± 41.77, p = 0.101 in week 2 compared to
control). Of note, we observed that combined FUS-
induced BBB opening with IL-12 administration provided
the most significant suppression of tumor progression
when compared to control (from 11.41 ± 8.52 to 4.75 ±
3.23, p = 0.1714 in week 1 and from 48.82 ± 30.17 to 3.60 ±
3.77, p = 0.002 in week 2 compared to control).
The animal survival among the experimental groups
is shown in Figure 8(B). FUS-BBB opening alone or IL-
12 administration alone had less tumor growth inhib-
ition and survival benefit when compared to control
(median survival = 23 and 26 days, respectively, com-
pared to 20 days or ISTmedian = 9.5% and 23.8%, re-
spectively; p = 0.116 and 0.004). IL-12 treatment alone
did inhibit tumor growth in the second week after
treatment and improved survival of brain tumor-
bearing rats. Of note, we observed that FUS-BBB open-
ing combined with IL-12 administration produced the
most powerful inhibition of tumor growth and survival
benefit (median survival = 30 days, or ISTmedian = 42.9%;
p <0.001). The detailed statistical results are shown in
Table 1.
Figure 7 Tumor progression followed by MRI. Representative T2 MR imaging to follow brain tumor progression (7 days observation time
interval; 3 time points in total) among the experimental groups.
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Significance of this study
In this study, we demonstrated the synergetic effect of
FUS-induced BBB opening combined with delivery of IL-
12 to enhance the therapeutic effect of anti-glioma treat-
ment in a preclinical small-animal study. We showed that
FUS-induced BBB opening did not trigger significant TIL
distribution changes, but did increase the total TIL num-
bers. While IL-12 administration significantly increased
both distribution and population percentages of TILs, it
did not contribute to end-point improvement as measured
by tumor progression control and survival. When FUS-Figure 8 Tumor progression and survival analysis. (A) Corresponding t
progression ratio with time interval between the 1st and 2nd MRI; week 2
3rd MRI. (n = 6 per group) (B) Kaplan–Meier plot demonstrating animal sur
groups, n = 13 for FUS and IL-12 + FUS groups).induced BBB opening was combined with IL-12 adminis-
tration, the enhanced local delivery of IL-12 into glioma
with the aid of transient opening of BBB successfully
changed the treatment outcome both in terms of tumor
progression control (from 2.4-fold to 13.5-fold of 7-day
tumor progression) and animal survival (42.9% of im-
prove). To our knowledge, this is the first report of FUS-
induced BBB opening as a tool for facilitating anticancer
immunotherapy against brain tumors. This study provides
important information for combining non-invasive fo-
cused ultrasound with therapeutics to locally trigger an
immune response for CNS disease treatment.umor progression ratio in four animal groups. Week 1 = tumor
= tumor progression ration with time interval between the 2nd and
vival among the experimental groups. (n = 12 for control and IL-12
Table 1 Efficacy of various treatment protocols for glioma-bearing animals among different experimental groups
Group (n) Median survival (days) ISTmedian (%) Mean survival (days) ISTmean (%) Maximal survival (days) p-value
Control (12) 21 — 21.5 — 28 —
FUS (13) 23 9.5 23.9 11.2 32 0.116
IL-12 (12) 26 23.8 25.5 18.6 35 0.004
IL-12 + FUS (13) 30 42.9 31.2 45.1 45 <0.001
Increase in median survival time (ISTmedian; in %), mean survival time (ISTmean; in %) and statistical analysis (Log-rank test and p-value) are all relative to the control
group (n = number of animals per group).
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Enhanced delivery of IL-12 for immunotherapy of gli-
oma has been attempted previously in both preclinical
and clinical studies. For preclinical evaluation, Kishima
et al. and Kikuchi et al. showed that survival can be im-
proved when IL-12 is systemically delivered in a preclin-
ical murine model [34,35]. Jean et al. demonstrated that
combined systemic IL-12 delivery with irradiation to
tumor cells can synergistically improved immunological
suppression of 9 L glioma progression in an animal
study [20]. On the other hand, DiMeco et al. used genet-
ically engineered 9 L glioma cells to express IL-12 as a
source of locally delivered cytokine IL-12 and also
showed improvement in animal survival [15]. Also, Liu
et al. demonstrated that delivery of IL-12 in a glioma ani-
mal treatment model had a similar tumor-suppressing ef-
fect and also found the anti-tumor immunity was
triggered by increased TIL infiltration, including CD4+
and CD8+ T lymphocytes [36,37], which is similar to the
observation in this study. In terms of clinical studies, Ren
et al. used convection-enhanced delivery to enhance IL-
12-expressing viral vectors in a phase I/II study, and
confirmed the safety of the approach and ability to locally
enhance IL-12 levels at the brain tumor site [38]. Kichuchi
et al. [39] also investigated the safety of combined infu-
sions of dendritic and glioma cells with recombinant IL-
12 for the treatment of malignant glioma in humans. In
their study, GBM patients showed significant reduction
(>50% in tumor mass reduction) of tumor burden, provid-
ing evidence of the glioma-suppressing effect of IL-12.
Mechanism of IL-12 in anticancer response
We demonstrated that FUS-induced BBB opening can
enhance IL-12 penetration and deposition at brain tu-
mors (shown in Figure 6) and therefore improve brain
tumor immunotherapy (Figure 8). The roles and mecha-
nisms of IL-12 as an immunological antitumor agent
have been exploited extensively since its discovery in the
1990s. IL-12 is physically secreted at the antigen site by
immune cells such as macrophages, B-cells, and micro-
glia. Also, in addition to being an important element in
the immune system, IL-12 is a potentially powerful anti-
tumor cytokine [40,41]. It has been shown that the pres-
ence of IL-12 can enhance proliferation of T cells[42,43], and also facilitate interferon (IFN)-gamma pro-
duction to promote Th-1-mediatedantitumor cytotoxic
immunity [44] (Th1, one of the CD4+ helper T cells
plays important roles in the enhancement of immunity)
and the associated anti-cancer immunological response
(IL-12 were reported to facilitate the development of
IFN-gamma-secreting tumor-specific Th1 T cells and
TILs, thereby enhancing the tumor-killing effects) [45].
In addition to the role of IL-12 in anticancer immuno-
logical responses, IL-12 can also regulate angiogenesis
and serve as an anti-angiogenic factor against tumor
progression [46,47].
Micro-environment changes caused by FUS-induced BBB
opening
Besides of direct IL-12 deposition to trigger brain cancer
immunotherapy, it is well known that FUS exposure in
the presence of microbubbles can increase vascular per-
meability. These capillary permeability changes in vari-
ous organs and tumor tissues possibly changes the
tumor micro-environment which is beneficial for trigger-
ing anti-cancer immunity [48-51]. A previous study by
Miller et al., in the absence of immunological observa-
tions, demonstrated a profound tumor suppression effect
within 4 days caused by FUS exposure in the presence of
microbubbles [52]. In this study, we confirmed that FUS
exposure combined with microbubbles can transiently
open the BBB, and we hypothesized that it provides tran-
sient micro-vascular and micro-environmental changes in
the tumor bed, leading to an increase in tumor cytokine/
chemokine release and triggering TIL infiltration. We also
observed that simply changes in the micro-environment
did not enhance systemic or local immunological response
in normal tissue, but did significantly induce the infiltra-
tion of CTLs into tumors and also increased the ratio of
CTL/Treg, which is a significant index of positive antican-
cer immune-triggering activity similar to that reported in
previous clinical studies [53,54].
Conclusion
In this study, we demonstrated enhanced local IL-12 de-
livery into glioma with the aid of FUS-induced transient
opening of BBB, which improved TIL infiltration, trig-
gered anticancer immunological response, and improved
Chen et al. Journal of Translational Medicine  (2015) 13:93 Page 11 of 12glioma treatment efficacy. This study provides useful
information regarding the use of FUS-induced BBB
opening to assist immune-modulating agent-enhanced
delivery to benefit anticancer immune response for brain
tumor treatment.
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